Core Viewpoint - Investors are currently rebalancing portfolios and strategizing for the upcoming year, with a focus on underperforming stocks, particularly UnitedHealth Group Inc, which has faced significant challenges in 2025 [1]. Group 1: Company Performance - UnitedHealth Group Inc (NYSE:UNH) is the worst performer on the Dow in 2025, primarily due to controversies following the murder of CEO Brian Thompson and a surprise earnings miss in April, leading to a lowered full-year outlook [2]. - The stock has seen a significant decline, losing more than 35% this year, with its price dropping to $324.13, marking its lowest level since April 2020 [3]. - The stock is on track to close out 2025 with only five monthly wins, indicating a prolonged period of underperformance [3]. Group 2: Market Sentiment and Volatility - Despite the underperformance, short-term options traders are leaning bullish, as indicated by a low Schaeffer's put/call open interest ratio, which ranks higher than only 4% of annual readings [5]. - The Schaeffer's Volatility Index (SVI) for UnitedHealth is at 30%, in the 19th percentile of its annual range, suggesting that near-term option traders are expecting low volatility [6]. - Historically, UnitedHealth has outperformed volatility expectations, as reflected in its Schaeffer's Volatility Scorecard (SVS) of 99 out of 100 [6].

Nashville, Tennessee-based HCA Healthcare, Inc. (HCA) is a healthcare services company that owns and operates a broad network of hospitals, surgery centers, freestanding emergency rooms, and urgent care clinics. Valued at a market cap of $107.7 billion, the company is scheduled to announce its fiscal Q4 earnings for 2025 in the near future. Before this event, analysts expect this healthcare giant to report a profit of $7.37 per share, up 18.5% from $6.22 per share in the year-ago quarter. The company has ...

Valued at a market capitalization of roughly $76.5 billion, Elevance Health, Inc. (ELV) positions itself as a lifelong, trusted health partner, driven by a mission to improve the health of humanity. The company supports individuals, families, and communities at every stage of the healthcare journey, connecting them with the care, tools, and resources needed to live healthier, more fulfilling lives. Through a broad and integrated portfolio spanning medical, pharmacy, behavioral, clinical, home health, and ...

Evolent Health, Inc. (NYSE:EVH) is one of the best healthcare AI stocks to buy now. On December 8, Evolent Health, Inc. (NYSE:EVH) revealed that it had completed the divestiture of its Accountable Care Organization (ACO) business to Privia Health Group, Inc. (NASDAQ:PRVA). The transaction, initially announced on September 23, 2025, was closed on Friday December 5. Evolent Health (EVH) Sells ACO Unit, Strengthens Balance Sheet Evolent received $100 million in cash at closing. The company could also earn a ...

SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Ardent Health, Inc. (NYSE: ARDT) focused on whether Ardent Health and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Ardent Health investigation or if you are an Ardent Health investor who suffered a loss and ...

近年来，合肥市双岗社区卫生服务中心在全省率先试点应用科大讯飞"智医助理"晓医系统。据相关负责 人介绍，这套全科辅助诊疗系统已无缝嵌入到医生的日常工作中，通过医学知识检索、智能辅助诊疗和 大数据推荐三大核心功能，结合患者的病情信息，实现智能诊断与相似病历推荐。 （来源：安徽新闻网） 转自：安徽新闻网 每周三趟、往返五十公里，这是庐江县泥河镇71岁肾病患者霍尚春曾经多年的日常。今年10月11日，庐 江县人民医院泥河分院血液透析室启用，他终于不必再像以前那样奔波，"在家门口就能血透，省时省 力还省钱。"霍尚春的话里透着欣慰。 据庐江县人民医院泥河分院院长李传文介绍，该院历时7个月建成的规范化血透室，总面积有300平方 米，配备了6台血液透析机，一举破解当地慢性肾病患者"透析难、奔波苦"的困局。 "硬件到位只是起点，关键是要让患者看得起病、看得放心。"他给记者算了一笔账，"每次透析费用 308.65元，我们院虽然是二级医院却执行一级医院收费标准，经医保统筹、慢性病门诊、低保及大病救 助等多重报销后，低保户个人仅需支付2.84元，普通患者单次自费也不过29元。最重要的是节约时间， 以前村民往返县城医院至少耗费三四个小时 ...

Core Viewpoint - The 8th Hainan International Health Industry Expo aims to promote the development of the health and wellness industry through collaboration and resource integration, with over 100 participants from various sectors attending the event [1][2]. Group 1: Event Overview - The "2025 Health Industry Project Supply and Demand Matching Conference" was held in Sanya, featuring multiple promotional activities and resulting in over ten signed cooperation projects [1]. - The conference serves as an efficient platform for industry connection, resource integration, and collaborative development among government, enterprises, capital, and think tanks [1]. Group 2: Industry Development - Hainan has significant advantages in developing the health and wellness service industry, including a suitable climate, abundant resources, and diverse wellness scenarios [1]. - Since 2019, Hainan has implemented a three-year action plan for the health industry, cultivating various business models such as medical wellness, traditional Chinese medicine wellness, and forest wellness, resulting in the establishment of 127 health industry projects [1]. Group 3: Policy Support - Hainan emphasizes the improvement of service functions and supports the classification of wellness institutions and enterprises, providing policy incentives in land planning, financial support, and health service functions [2]. - The launch of the Hainan Free Trade Port has accelerated the construction of a differentiated health industry cluster, marking a period of policy benefits and opportunities for the wellness industry [2]. Group 4: Cooperation Outcomes - The signing of cooperation projects at the conference includes international collaboration, industry integration, and medical education research, with an intended signing amount exceeding 600 million yuan [3]. - Notable partnerships include collaborations between Hainan companies and international firms, as well as agreements with health and wellness associations and educational institutions [3].

Core Insights - Tempus AI (TEM) is showing early signs of profitability with its first positive Adjusted EBITDA in Q3 2025 and has raised its full-year revenue guidance [1][7] - The company is focusing on improving cost control and operating leverage as revenues scale, despite the Paige acquisition impacting near-term profitability [1][2] Financial Performance - Gross profit nearly doubled year-over-year in Q3 2025, driven by growth in Genomics and Data services [2][7] - Fourth-quarter 2025 Adjusted EBITDA is expected to remain positive, supported by growth trends across business segments [2] - Despite positive Adjusted EBITDA, GAAP losses continue due to stock-based compensation and other non-cash items, limiting visibility into sustainable GAAP profitability [3][7] Peer Comparison - Hims & Hers Health, Inc. (HIMS) reported robust revenue growth nearing $600 million in Q3 2025 and achieved positive net income, reflecting a transition in profitability [4] - GoodRx Holdings, Inc. (GDRX) is maintaining stable revenues while shifting towards higher-margin solutions, focusing on margin durability amid evolving growth models [5] Stock Performance - Over the past year, Tempus' shares have increased by 81.4%, significantly outperforming the industry, which declined by 2.4% [6] - TEM currently trades at a forward Price-to-Sales (P/S) ratio of 7.42X, higher than the industry average of 5.77X, indicating an expensive valuation [8]

Market Performance - Benchmark indices opened positively, with the Sensex rising 468.44 points (0.55%) to 84,950.25 and the Nifty gaining 133.90 points (0.52%) to 25,949.45, driven by favorable global cues following lower-than-expected US inflation data [1] - The Sensex closed at 84,481.81 and the Nifty at 25,815.55 in the previous session, indicating a continuation of gains as both indices opened higher at 84,756.79 and 25,911.50 respectively [2] Global Market Influence - Global markets showed a positive bias, led by gains in US equities after the November consumer price inflation data came in at 2.7%, lower than anticipated, which bolstered expectations for further interest rate cuts by the US Federal Reserve [3] - The Nasdaq surged 1.38%, while the S&P 500 and Dow Jones increased by 0.79% and 0.14% respectively, reflecting a shift towards a risk-on environment [3] Sector Performance - Among the top gainers on the Nifty 50, Max Healthcare Institute led with a 1.91% increase to ₹1,068.50, followed by Tata Motors Passenger Vehicles up 1.87% to ₹352.25, and Bharat Electronics gaining 1.81% to ₹390.40 [4] - On the losing side, Shriram Finance declined by 1.20% to ₹859, while HCL Technologies fell 0.34% to ₹1,655.70 [5] Institutional Activity - Foreign Institutional Investors (FIIs) continued buying for a second consecutive session, purchasing equities worth nearly ₹600 crore, while Domestic Institutional Investors showed strong buying interest with inflows of ₹2,700 crore [6] Technical Analysis - The Nifty 50 is in a consolidation phase, trading within the 25,700–25,900 range, with immediate resistance at 25,900–26,000 and key supports at 25,700 and 25,600 [7] - The Indian rupee appreciated by 14 paise to settle at 90.24 against the US dollar, marking a second consecutive day of gains [7]

Group 1 - The Wasatch Micro-Cap Fund reported a return of 9.52% in Q3 2025, underperforming the benchmark Russell Microcap® Growth Index, which returned 19.93% [1] - The Pennant Group, Inc. (NASDAQ:PNTG) is highlighted as a key stock, with a one-month return of 13.43% and a 52-week gain of 7.66% [2] - The Pennant Group, Inc. reported revenue of $229 million in Q3 2025, reflecting an increase of $48.4 million or 26.8% from Q3 2024 [4] Group 2 - The Pennant Group operates a network of senior-living facilities and home-health agencies, focusing on purchasing underutilized assets to drive patient volumes [3] - Concerns regarding proposed Medicare reimbursement rates negatively impacted sentiment for The Pennant Group's stock, although expectations for a more favorable final rate structure could support recovery [3] - The number of hedge funds holding The Pennant Group increased from 27 to 30 in Q3 2025, indicating growing interest [4]